SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

ViaDerma Inc. (VDRM)

VDRM RSS Feed
Add VDRM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, trop, Clonefan, GreenBrickRoad, ddtburg
Search This Board: 
Last Post: 4/28/2017 1:44:30 PM - Followers: 471 - Board type: Free - Posts Today: 21


VDRM

ViaDerma, Inc.

A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.

APPLICATIONS & USAGE

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year
     

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Contact Details

ViaDerma's global headquarters is located at
4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744

Email:  info@viadermalicensing.com

LINKS TO:
 

                             Most Recent News    

Most Recent Filings and Disclosures

 

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 

Authorized Shares: 400,000,000 a/o April 17, 2017

Outstanding Shares: 340,714,603 a/o April 17, 2017

(Restricted 54,475,478 - Unrestriced 286,239,125)

Held at DTC - 286,227,109 a/o April 17, 2017

Float: 222,337,825 a/o Jan 25, 2017

Par Value    0.001

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

$VDRM COULD BE THE pharmacy stock of the year. This stock could run 30,000% here's why.

1) EXTREMELY OVERSOLD and unknown 
2) ONLY 150 MILLION A\S! Makes it the TINIEST FLOAT VS PRICE out of ALL pharmacy stockso in the whole country!
3) Pharmaceutical stocks have the LARGEST PERCENTAGE GAINS OUT OF ALL STOCKS IN THE MARKET on the big boards or the OTHER. 
4) Unusual sudden MASSIVE increase in volume since 3/7/16 LOOK.
5) INSIDERS OWN 75 MILLION SHARES, that's right 75 MILLION!
6) WON AWARD FOR THEIR DRUG
7) STRONG HANDS HOLDING 11 million shares out of the TINY 18 million float.
8) After being silent for ages 4 JUICY FILINGS came out in September so something could be up.
9) THEY HAVE A PATENT which big boys have to be eyeing.

VDRM IS A HIDDEN GOLDMINE

THIS IS NOT A REGULAR PENNY STOCK. The LOWEST FLOAT vs price vs ALL PHARMA STOCKS IN THE COUNTRY. BIG BOARD OR OTC LAND. ALL OF THEM. Pharma stocks have the HIGHIGHEST EST percentage gain in big boards or penny stocks

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HUGE:
 

VDRM ENTERS MMJ PLAYING FIELD

LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.


 

THE SECTION BELOW WAS DEVELOPED BY NEPTUNE/MISTRAL - LAST UPDATE 04.20.17
Text in blue font contains hyperlinks to detailed information.
 

Authorized  400,000,000   -   Issued & Outstanding  340,714,603   -   Restricted  54,475,478  -   Unrestricted 286,239,125

Confirmed by Transfer Agent March 31, 2017
Clear Trust LLC 813-235-4490

 

VIADERMA REGISTRATION     -     OTC PINK - UNAUDITED     -     VIADERMA II REGISTRATION

  

ViaDerma, Inc. is a specialty pharmaceutical company founded in 2014 by Dr. Chris Ayo Otiko, a Podiatrist.  Their current lead product is an FDA-registered
topical antibiotic called Viabecline that the Company manufactures and distributes under a
non-exclusive licensing and distribution agreement with Dr. Howard Phillips
of
the
Phillips Company, the world's only FDA-registered drug manufacturer that operates as a not-for-profit pharmaceutical research company.


Phillips transfers their technology and brand names to any company that can produce their new drugs in high volume, at low cost, and "take it to the people." 

Mr. Phillips has confirmed that ViaDerma has both a distributor's agreement for  Phillips-manufactured products; and a manufacturing
license for one product -- Diabecline or Viabecline.
National Library of Medicine Label Information is linked to Medication Name.
Ingredients are noted below for ease of comparison. Viabecline has two extra ingredients.

 
DIABECLINE VIABECLINE
Active
Ingredients
Tetracycline Hydrochloride 30 mg Active
Ingredients
Tetracycline Hydrochloride 30 mg
Inactive
Ingredients

Ascorbic Acid, Chlorhexidine Gluconate,
Cholecalciferol, Dimethyl Sulfoxide, Dipropylene Glycol,
Glucono Delta Lactone, Glycerin,

Hydroxethylc-Cellulose, Magnesium Stearate, Methylparaben,
Sodium Hydroxide, Sorbic Acid, Steric Acid, Water.
Inactive
Ingredients
Acetic Acid
Ascorbic Acid, Chlorhexidine Gluconate,
Cholecalciferol, Dimethyl Sulfoxide, Dipropylene Glycol,
Glucono Delta Lactone, Glycerin,

Histidine
Hydroxethylc-Cellulose, Magnesium Stearate, Methylparaben,
Sodium Hydroxide, Sorbic Acid, Steric Acid, Water.
     Sources:  U.S. Library of Medicine DailyMed and National Drug Codes List

NO MANUFACTURING LICENSE HAS BEEN ISSUED FOR TETRA STEM

Phillips Company's FDA Registered Pharma Products

Along with Steven J. Keough, Dr. Phillips is a named inventor of the patent-pending "Topical Drug Delivery System with Dual Carriers" on which Viabecline is based.
This invention is Published under two US Patent Application Numbers: 
US 20130190274  A1 and US 20120070390 A1 and through the WIPO. The Applicant was Pharmacline.


Dr. Phillips has retained a small-batch license (<20,000 Units) for Diabecline.  Thru Pharma LLC owns the Diabecline Trademark.

Steven J. Keough, the CEO of Thru Pharma LLC dba Dakota Life Sciences (now merged with Kasten OTC:PK KAST)  has confirmed their intention to protect
their patent-pending technology.  Dakota Life Sciences is engaged in developing
innovative health products utilizing Site Specific Penetration Technology SSPT™ technologies.
These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony™ OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™
RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as other valuable life sciences technologies.


"We believe in the core technology, and have solid plans to use it going forward. We did a voluntary recall in 2014 for the Diabecline branded antibiotic swab
because the formulation was causing deterioration of the swab tip. We will not have that configuration going forward, but will be using and protecting the technology."
--Steven J. Keough via email to shareholder March 5, 2017 -
Post 13474


In describing their use of this jointly-owned patent-pending invention, Keough's entities use their trademarked term
"Site Specific Penetration Technology™" and Otiko references his use of the Phillips/Keough patent as "proprietary innovative transdermal delivery system."


Two USPTO provisional application numbers were first shared by Otiko on March 20, 2017  for "two patents pending" (an inaccurate term).  See IP table below.
Provisionals establish an early filing date but do not mature into an issued patent unless the provisional is followed up with a patent application within a year.
While Dr. Otiko has referenced patent applications that have been submitted since 2014, no record of any applications show in a search of the USPTO Pair System.


"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

 
INTELLECTUAL PROPERTY FILED BY DR. CHRIS AYO OTIKO
 PATENTS TRADEMARKS
NAME NUMBER NOTES NAME NUMBER STATUS
2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
 
WAYBACK MACHINE CRAWL DATA
These are website capture dates, not the date content was updated.
CRAWL DATE LEAD PRODUCT ANNOUNCED ON WEBSITE ANNUAL SALES ANNUAL NET INCOME/LOSS WEBSITE COPYRIGHT YEAR
05/31/14 ViaDerma's proprietary transdermal delivery system     2014
10/18/14 ViaDerma's proprietary transdermal delivery system 130,859 (2014) -6,473,732 (2014) 2014
02/18/15 TetraStem     2014
04/11/15 TetraStem     2014
09/26/15 TetraStem 191,777 (2015) 27,121 (2015) 2014
01/11/16 TetraStem     2014
03/02/16 TetraStem     2014
03/04/16 TetraStem     2014
03/26/16 TetraStem     2014
05/17/16 TetraStem     2014
10/06/16 Diabecline     2014
02/10/17 Diabecline     2017
 
VIADERMA'S ANNOUNCED DISTRIBUTORS
Business Name Owner Registered Otiko's Role
BIOGENX
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
TBD
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
TBD CA
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.
 

RECENT NEWS

04/19/17 - ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks

04/05/17 - ViaDerma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration (FDA) for a New OTC Drug to Conquer Premature Ejaculation for Men

03/20/17 - ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

03/08/17 - ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

02/15/17 - ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

02/08/17 - Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes
Science and Technology, a leading US Publication for Diabetes


02/03/17 - ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017,
also  Onychomycosis Clinical Studies Show Significant Results


01/11/17 - ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling
Viabecline Through Established Online Distribution Networks in 2017


12/09/16 - Video with Dr. Otiko by Jasyn Blair of Uptick Newswire - Notes

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VDRM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#20089  Sticky Note ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Hummingbird2 04/19/17 03:35:56 PM
#20071  Sticky Note Keough paid Phillips $300,000.00 for full ownership rights Mistral 04/19/17 02:01:10 PM
#14800  Sticky Note ViaDerma = $$'s coming this year! Here's all whatarush12 03/12/17 09:59:04 PM
#13415  Sticky Note EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/17 10:10:04 AM
#20911   what is the realistic price we can see tganz 04/28/17 01:44:30 PM
#20910   And don't forget everything in the pipeline! MegaVerde 04/28/17 01:21:33 PM
#20909   NICE POST MOMO... Lambsheadranch 04/28/17 01:19:52 PM
#20908   can you let me know what kind of tganz 04/28/17 01:01:25 PM
#20907   $VDRM SHORTSQUEEZE IMMINENT. HEAVY SHORTING THROUGH CITADEL, Momostocktrades 04/28/17 12:15:43 PM
#20906   We will go on a multi week run whatarush12 04/28/17 12:05:56 PM
#20904   Thanks guys. :) Lucky Fellow 04/28/17 11:28:33 AM
#20903   up on this site hans1111 04/28/17 11:20:49 AM
#20902   Its a little high, but the revenue potential kennyt 335 04/28/17 10:16:03 AM
#20901   It's less than the float dol*, and more Beano1969 04/28/17 10:14:21 AM
#20900   That seems pretty high for float??? Or is N-Deep 04/28/17 10:02:31 AM
#20899   I just added another 1 mil shares. Now retired early 04/28/17 10:00:37 AM
#20898   *Yuuge hit right there* freshy 04/28/17 09:53:39 AM
#20897   As I understand it... MegaVerde 04/28/17 09:37:36 AM
#20896   Dip is around .012......as of now the way RebelliousWolf 04/28/17 09:26:19 AM
#20895   So I've been away for a bit what's Lucky Fellow 04/28/17 08:55:40 AM
#20894   Let's see if we can use that special Rubyt 04/28/17 08:40:47 AM
#20893   Yes that is what I see too. 222, Beano1969 04/28/17 07:57:11 AM
#20892   Verry low Floater..nice freshy 04/28/17 07:27:25 AM
#20891   Awesome,thank-you. That is really low! Peace! Zenguy 04/28/17 07:01:32 AM
#20890   Where do you see that figure? Otcmarkets.com shows Bob87 04/27/17 09:39:42 PM
#20887   Float: 51,061,509 hans1111 04/27/17 06:20:20 PM
#20886   How we hope you're right. goodvibe60 04/27/17 06:04:54 PM
#20885   Be smart shorts and cover, gonna run north soon!! kennyt 335 04/27/17 05:40:41 PM
#20884   What a great scam stock to burn the kennyt 335 04/27/17 05:39:22 PM
#20883   Really seems that $VDRM has set the bottom. SouredStock4 04/27/17 04:30:19 PM
#20882   Quick question...new to this stock, just bought in Zenguy 04/27/17 04:13:56 PM
#20879   The scam is Keough thinking he's owed something XFactor22 04/27/17 03:27:58 PM
#20878   Buy before end of the month.. short positions freshy 04/27/17 03:25:41 PM
#20877   Such a scam its worth suing? Riiiiiight XFactor22 04/27/17 03:23:35 PM
#20876   NOTHING stable about VDRM at all! Jenius Jay 04/27/17 03:23:17 PM
#20875   What a SCAM LOL!! Jenius Jay 04/27/17 03:14:35 PM
#20874   Stable...All up from here imo XFactor22 04/27/17 03:11:03 PM
#20873   Many "what ifs" regarding FDA approval, but what micar 04/27/17 02:00:36 PM
#20872   Picked up another 550K. sunasuna1 04/27/17 01:01:47 PM
#20871   If CEO Otiko is right on his VDRM thiefscamfraud 04/27/17 12:45:34 PM
#20870   What's the PR going to be about though? Thanks EricAugustusLee99 04/27/17 12:32:56 PM
#20869   PR from 4/5/17 means MID MAY for Approval...Viaderma Braden32601 04/27/17 12:01:37 PM
#20868   http://oracledispatch.com/2017/04/26/viaderma-inc-otcmktsvdrm-innovative-co-cann casinoo 04/27/17 11:45:51 AM
#20867   Grab this!!! FDA approval imminent.. freshy 04/27/17 11:44:59 AM
#20865   Lets hit $1 first;) whatarush12 04/27/17 11:07:02 AM
#20864   VDRM High of the Day Nice $$ Braden32601 04/27/17 10:48:16 AM
#20862   Green! Hope it lasts MegaVerde 04/27/17 10:39:50 AM
#20861   Great BID support, over 4mill on level2 whatarush12 04/27/17 10:39:21 AM
#20860   Shameful MM's! Us regular Joe's/Jane's don't stand a Bartletpear 04/27/17 10:07:16 AM
#20859   buying...love these cheap shares XFactor22 04/27/17 10:06:28 AM
#20858   BUY ALL YOU BEFORE ITS TOO LATE MeLotsOfMoney 04/27/17 10:04:17 AM
#20856   What is may going to do with our stocks? chico2663 04/27/17 09:53:11 AM
#20855   May almost here!! freshy 04/27/17 09:33:24 AM
#20854   Great DD on VDRM! Including Price Targets..$$ Braden32601 04/27/17 09:18:36 AM
PostSubject